Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Dec 9, 2014; 3(4): 97-109
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.97
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.97
Patents on antivirulence therapies
María López, Eva Gato, Germán Bou, María Tomás, Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, 15006 La Coruña, Spain
Beathriz Barbosa, Departamento de Microbiologia, Imunologia e Parasitologia - FCM/UERJ, 20551-030 Rio de Janeiro, Brazil
Author contributions: All authors contributed to this work.
Supported by Instituto de Salud Carlos III FEDER, Spanish Network for the Research in Infectious Diseases, No. REIPI RD12/0015; by the Spanish Ministry of Health and FEDER funding, No. FIS PI10/00056-PI13/02390 (to Tomás M) and PI12/00552 (to Bou G); and by the Miguel Servet Programme (C.H.U.A. Coruña and ISCIII) (to Tomás M)
Correspondence to: María Tomás, MD, PhD, Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña-INIBIC, As Xubias, 84, 15006 La Coruña, Spain. ma.del.mar.tomas.carmona@sergas.es
Telephone: +34-98-1176399 Fax: +34-98-1178273
Received: June 28, 2014
Revised: October 30, 2014
Accepted: November 7, 2014
Published online: December 9, 2014
Revised: October 30, 2014
Accepted: November 7, 2014
Published online: December 9, 2014
Core Tip
Core tip: Antimicrobial resistance in nosocomial pathogens has increased dramatically in recent years. The development of new molecules, therapies and/or new combinations for the eradication of these pathogens is therefore imperative. A new line of research in this area is called “Antivirulence Therapy”.